Company news

Envveno Medical Corporation (NASDAQ:NVNO) news

Envveno Medical Corporation news releases on 6ix. Latest, Sep 16, 2026: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

Envveno Medical Corporation (NASDAQ:NVNO) news

Press releases & updates

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

enVVeno Medical Announces Reverse Stock Split

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

enVVeno Medical Updates Regulatory Status of VenoValve(R)

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

EnVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H25

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

EnVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

EnVVeno Medical : Proxy Results Form 8 K

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

EnVVeno Medical Reports Third Quarter 2024 Financial Results

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

enVVeno Medical Corporation Announces Proposed Public Offering

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

EnVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)